Gastroparesis Treatment Market, By Drug Class (Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Others), By Disease Indication (Diabetes Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), By Type (Over-the-Counter Drugs and

Gastroparesis Treatment Market, By Drug Class (Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Others), By Disease Indication (Diabetes Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), By Type (Over-the-Counter Drugs and Prescription Drugs), By Route of Administration (Oral, Injectables, Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Global gastroparesis treatment market growth is driven by rising prevalence of diabetes and idiopathic gastroparesis. Gastroparesis, or delayed stomach emptying, is a chronic disorder, in which the stomach takes too long to empty its contents. Patients suffering from gastroparesis experience nausea, vomiting, bloating and fullness after eating. Currently, there is no cure for gastroparesis and the available treatment options focus on managing the symptoms. Rising research and development activities related to new drug development can drive the market growth.

Market Dynamics:

Global gastroparesis treatment market growth is driven by factors such as increasing diabetic population, rising prevalence of idiopathic gastroparesis, growing awareness about gastroparesis among people and physicians. However, poor patient compliance associated with oral medication, non-availability of effective treatment and side effects of drug therapies can hamper the market growth. Development of novel drugs with better efficacy and less side effects can offer lucrative growth opportunities in the market.

Key features of the study:

• This report provides in-depth analysis of the global gastroparesis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global gastroparesis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson & Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment market

Detailed Segmentation-

• Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
• Prokinetic Agents
• Antiemetic Drugs
• Proton Pump Inhibitors
• Others (Botulinum Toxin Injections, etc.)
• Disease Indication Insights (Revenue, USD Bn, 2019 - 2031)
• Diabetes Gastroparesis
• Idiopathic Gastroparesis
• Post-surgical Gastroparesis
• Type Insights (Revenue, USD Bn, 2019 - 2031)
• Over-the-Counter Drugs
• Prescription Drugs
• Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
• Oral
• Injectables
• Nasal
• Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Evoke Pharma, Inc.
• Processa Pharmaceuticals, Inc.
• Neurogastrx, Inc.
• Vanda Pharmaceuticals Inc.
• ANI Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Otsuka Holdings Co., Ltd.
• CinDome Pharma, Inc.
• PTC Therapeutics
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Atlantic Healthcare
• Salix Pharmaceuticals
• Rhythm Pharmaceuticals, Inc.
• Ironwood Pharmaceuticals, Inc.
• Medtronic plc
• Bausch Health Companies Inc.
• Sanofi S.A.